RxDoctor Payments Data

Nathan Neuberger, DO

Family Medicine · Des Moines, IANPI 1922459494

Payments from drug & device makers

$1,030in general payments, 2019–2025

Across 60 payments — averaging $17.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$262
  • AbbVie$219
  • Otsuka America Pharmaceutical, Inc.$55
  • Welch Allyn$45
  • AstraZeneca$43
  • Mannkind Corporation$43
  • plus $363 from 17 others

What the payments were for

  • Food & beverage$96594%
  • Education$202%
  • Other$454%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,030 in reported general payments places this provider in the 80th percentile of 1,357 family medicine providers in Iowa.

See all family medicine providers in Iowa

Medicare billing

Part B allowed, 2024
$319,371
Medicare patients
393
Services billed
6,097

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban224$188,186
JardianceEmpagliflozin159$129,993
TrulicityDulaglutide84$79,601
OzempicSemaglutide83$79,103
MounjaroTirzepatide77$75,011
Trelegy ElliptaFluticasone/Umeclidin/Vilanter93$72,398
RexultiBrexpiprazole34$50,066
XareltoRivaroxaban65$44,132
JanuviaSitagliptin Phosphate46$30,989
MyrbetriqMirabegron24$17,195
RybelsusSemaglutide17$16,225
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog33$13,200
Breo ElliptaFluticasone/Vilanterol31$12,957
Spiriva HandihalerTiotropium Bromide15$10,322
Aimovig AutoinjectorErenumab-Aooe11$8,989

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Premarin$17$190,678236 claims
Lilly USA, LLCTrulicity, Mounjaro$30$154,612161 claims
Boehringer IngelheimJardiance$32$129,993159 claims
Novo NordiskOzempic, Rybelsus$29$95,328100 claims
Otsuka America Pharmaceutical, Inc.Rexulti$55$50,06634 claims
Johnson & JohnsonXarelto$38$44,13265 claims
AstraZenecaSymbicort$43$7,38826 claims
Sanofi-aventis U.S. LLCLantus$16$1,86216 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,357 family medicine providers in Iowa.

Other family medicine in Des Moines

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →